PMID- 33139612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 1
TI  - Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer.
LID - 10.3390/cancers12113224 [doi]
LID - 3224
AB  - Extended small cell lung cancer (ED-SCLC) is a very aggressive disease, 
      characterized by rapid growth and an early tendency to relapse. In contrast to 
      non-small cell lung cancer, no therapeutic innovation has improved survival in 
      patients with ED-SCLC over the past 20 years. Recently, immunotherapy has shown 
      an important role in the management of these patients, emerging as the treatment 
      of first choice in combination with chemotherapy and completely changing the 
      therapeutic paradigm. However, patients' selection for this strategy is still 
      challenging due to a lack of reliable predictive biomarkers. Conversely, the 
      immunotherapy efficacy beyond the first line is pretty disappointing and 
      innovative chemotherapies or target agents seem to be more promising in this 
      setting. Some of them are also under evaluation as an upfront strategy and they 
      will probably change the treatment algorithm in the next future. This proposal 
      provides a comprehensive overview of available treatment strategies for ED-SCLC 
      patients, highlighting their strengths and weaknesses.
FAU - Pierret, Thomas
AU  - Pierret T
AUID- ORCID: 0000-0002-4297-7413
AD  - Thoracic Oncology Unit, CHU Grenoble-Alpes, 38700 Grenoble, France.
FAU - Toffart, Anne-Claire
AU  - Toffart AC
AD  - Thoracic Oncology Unit, CHU Grenoble-Alpes, 38700 Grenoble, France.
FAU - Giaj Levra, Matteo
AU  - Giaj Levra M
AD  - Thoracic Oncology Unit, CHU Grenoble-Alpes, 38700 Grenoble, France.
FAU - Moro-Sibilot, Denis
AU  - Moro-Sibilot D
AD  - Thoracic Oncology Unit, CHU Grenoble-Alpes, 38700 Grenoble, France.
FAU - Gobbini, Elisa
AU  - Gobbini E
AD  - Thoracic Oncology Unit, CHU Grenoble-Alpes, 38700 Grenoble, France.
AD  - Cancer Research Center of Lyon, 69008 Lyon, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201101
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7692868
OTO - NOTNLM
OT  - extended small cell lung cancer
OT  - immunotherapy
OT  - target agents
COIS- E.G. received personal fees from AstraZeneca, Roche, Merck Sharpe and Dohme and 
      Bristol-Myers Squibb, as well as research grant from Bristol-Myers Squibb outside 
      the submitted work. DMS received personal fees from Roche, Merck Sharpe and 
      Dohme, Bristol-Myers Squibb, and AstraZeneca outside the submitted work. ACT 
      received personal fees from AstraZeneca, Roche, Merck Sharpe and Dohme and 
      Bristol-Myers Squibb, outside the submitted work. MGL received personal fees from 
      AstraZeneca, Roche, Merck Sharpe and Dohme and Bristol-Myers Squibb, outside the 
      submitted work. T.P. declares personal fees received from BMS.
EDAT- 2020/11/04 06:00
MHDA- 2020/11/04 06:01
PMCR- 2020/11/01
CRDT- 2020/11/03 05:40
PHST- 2020/09/29 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/03 05:40 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/11/04 06:01 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - cancers12113224 [pii]
AID - cancers-12-03224 [pii]
AID - 10.3390/cancers12113224 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Nov 1;12(11):3224. doi: 10.3390/cancers12113224.